ReviewFrontiers in pharmacology2020

First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress.

Zhangfeng Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.